You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Colorcon
Dow
Merck
Mallinckrodt

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRESSA

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Iressa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005806 Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00005806 Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer.
NCT00006048 ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00006049 ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Unknown status AstraZeneca Phase 3 2000-05-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer.
NCT00012337 ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed National Cancer Institute (NCI) Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
NCT00012337 ZD 1839 in Treating Patients With Metastatic Kidney Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-01-01 RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iressa

Condition Name

Condition Name for Iressa
Intervention Trials
Non-Small Cell Lung Cancer 28
Lung Cancer 23
Breast Cancer 17
Head and Neck Cancer 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iressa
Intervention Trials
Carcinoma, Non-Small-Cell Lung 95
Lung Neoplasms 82
Breast Neoplasms 23
Head and Neck Neoplasms 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iressa

Trials by Country

Trials by Country for Iressa
Location Trials
United States 363
China 79
Italy 55
Japan 45
Canada 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iressa
Location Trials
Texas 22
New York 21
California 20
Massachusetts 19
Pennsylvania 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iressa

Clinical Trial Phase

Clinical Trial Phase for Iressa
Clinical Trial Phase Trials
Phase 4 7
Phase 3 37
Phase 2/Phase 3 4
[disabled in preview] 179
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iressa
Clinical Trial Phase Trials
Completed 142
Terminated 25
Unknown status 19
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iressa

Sponsor Name

Sponsor Name for Iressa
Sponsor Trials
AstraZeneca 103
National Cancer Institute (NCI) 51
Massachusetts General Hospital 7
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iressa
Sponsor Trials
Other 196
Industry 133
NIH 53
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Dow
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.